Stock DNA
Pharmaceuticals & Biotechnology
CNY 7,135 Million (Mid Cap)
NA (Loss Making)
NA
1.59%
0.24
-4.64%
1.10
Revenue and Profits:
Net Sales:
2,629 Million
(Quarterly Results - Sep 2025)
Net Profit:
100 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
27.35%
0%
27.35%
6 Months
76.74%
0%
76.74%
1 Year
82.49%
0%
82.49%
2 Years
-7.82%
0%
-7.82%
3 Years
-20.81%
0%
-20.81%
4 Years
-39.59%
0%
-39.59%
5 Years
-21.47%
0%
-21.47%
Dian Diagnostics Group Co. Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
4.07%
EBIT Growth (5y)
-158.57%
EBIT to Interest (avg)
7.00
Debt to EBITDA (avg)
1.18
Net Debt to Equity (avg)
0.23
Sales to Capital Employed (avg)
1.15
Tax Ratio
75.66%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0.12%
ROCE (avg)
19.28%
ROE (avg)
19.22%
Valuation key factors
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
1.10
EV to EBIT
-105.31
EV to EBITDA
15.33
EV to Capital Employed
1.08
EV to Sales
0.84
PEG Ratio
NA
Dividend Yield
1.60%
ROCE (Latest)
-1.03%
ROE (Latest)
-4.17%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
Bearish
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bearish
No Trend
Shareholding Snapshot : Dec 2016
Shareholding Compare (%holding) 
Majority shareholders
Foreign Institutions
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 1 Foreign Institutions (0.12%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Sep'25 - QoQ
Sep'25
Jun'25
Change(%)
Net Sales
2,629.10
2,571.40
2.24%
Operating Profit (PBDIT) excl Other Income
185.80
242.20
-23.29%
Interest
32.20
33.90
-5.01%
Exceptional Items
4.10
4.80
-14.58%
Consolidate Net Profit
99.80
78.00
27.95%
Operating Profit Margin (Excl OI)
70.70%
34.30%
3.64%
USD in Million.
Net Sales
QoQ Growth in quarter ended Sep 2025 is 2.24% vs 9.19% in Jun 2025
Consolidated Net Profit
QoQ Growth in quarter ended Sep 2025 is 27.95% vs 1,757.14% in Jun 2025
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
12,166.60
13,373.70
-9.03%
Operating Profit (PBDIT) excl Other Income
1,226.90
1,790.10
-31.46%
Interest
221.70
263.20
-15.77%
Exceptional Items
-424.20
-2.30
-18,343.48%
Consolidate Net Profit
-169.20
581.60
-129.09%
Operating Profit Margin (Excl OI)
41.20%
74.60%
-3.34%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -9.03% vs -33.91% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -129.09% vs -68.77% in Dec 2023
About Dian Diagnostics Group Co. Ltd. 
Dian Diagnostics Group Co. Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






